Clinical Trial Update: Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of mogamulizumab in combination with extracorporeal photopheresis for Sezary syndrome and mycosis fungoides was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Non-hodgkin Lymphoma
• Mycosis Fungoides
• Sezary Syndrome

Drugs mentioned

• POTELIGIO (mogamulizumab)

Snippet

Sponsor: Emory University | Conditions: Mycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: TERMINATED